292P - Serum levels of VEGF pre- and post-treatment with bevacizumab (BEV) for early stage breast cancer (ESBC): ICORG 08-10

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Translational Research
Breast Cancer
Basic Principles in the Management and Treatment (of cancer)
Presenter Alexandra Canonici
Authors A.M. Canonici1, I. Parker2, T. O'Shea2, B. Moulton2, G. Gullo3, M..J. Kennedy4, D. Tryfonopoulos5, N. Walsh6, N. O'Donovan6, J.P. Crown7
  • 1Nicb, Dublin City University, 9 - Dublin 9/IE
  • 2Icorg, ICORG, Dublin 2/IE
  • 3St Vincent's University Hospital, Department of medical Oncology, Dublin 4/IE
  • 4St James's Hospital, IE-8 - Dublin/IE
  • 5Medical Oncology Unit, St Vincents University Hospital, IE-4 - Dublin 4/IE
  • 6National Institute For Cellular Biotechnology,, Molecular Therapeutics for Cancer Ireland, Dublin City University, 9 - Dublin 9/IE
  • 7Department Of Medical Oncology, St Vincents University Hospital, IE-4 - Dublin /IE



Angiogenesis, partly mediated by vascular endothelial growth factor (VEGF), promotes metastases. BEV, an anti-VEGF monoclonal antibody which has some efficacy in metastatic BC is being studied as an adjuvant treatment for ESBC. However, there are no validated biomarkers, and the effects of BEV on VEGF levels in pts with ESBC is unknown. We studied VEGF serum concentration in ESBC receiving BEV.


106 pts with HER-2 negative ESBC were included in this study. Patients received 4 cycles of docetaxel (75 mg/m2) + cyclophosphamide (600 mg/m2) with BEV (15 mg/kg) once every three weeks for one year. Serum samples were collected prior to commencement of treatment, at 6 months and 12 months. The VEGF levels in serum samples were determined, at each time point, using a VEGF enzyme-linked immunosorbent assay (ELISA).


VEGF concentration was determined in serum samples from 65 patients. Serum VEGF was detectable in 62 of 65 patients and the median level in untreated patients was 325.4 pg/ml (range 0.1 - 924.8 pg/ml). All of the 62 patients showed a significant decrease in VEGF concentration after 6 and 12 months of treatment (median 9 ± 42.1 pg/ml, p < 0.001 and 9 ± 43.9 pg/ml, p < 0.001 respectively). No significant change in median VEGF levels observed at 12 months compared to 6 months (median 0 ± 60.3 pg/ml, p = 0.704). However, in 14 patients the levels of VEGF detected at 12 months were higher than at 6 months following treatment (p = 0.045).


Adjuvant therapy with chemotherapy and BEV is associated with a significant reduction in VEGF levels at 6 months.


All authors have declared no conflicts of interest.